María Cristina Saccheri

María Cristina Saccheri

Auto-generated profile, based on publicly available information

María Cristina Saccheri

Division of Cardiology, Cardiology Department, Hospital of the Government of the City of Buenos Aires “Dr. Cosme Argerich”, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2020 in Echocardiography
Verified
Journal Article
Closed access
PDF file
TCTomas F. Cianciulli
Tomas F. Cianciulli
MSMaría C. Saccheri
María C. Saccheri
MRMario A. Rísolo
Mario A. Rísolo
JLJorge A. Lax
Jorge A. Lax
RMRicardo J. Méndez
Ricardo J. Méndez
LKLucia R. Kazelián
Lucia R. Kazelián

29 May 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
MSMaría C Saccheri
María C Saccheri
TCTomás F Cianciulli
Tomás F Cianciulli
FBFederico L Blanco
Federico L Blanco
RBRodrigo I Blanco
Rodrigo I Blanco
Fabry disease (FD) is a rare lysosomal storage disease, caused by mutations in the gene encoding the enzyme α-galactosidase A (α-Gal A). Cardiac involvement is one of the main causes of death and it is characterized by progressive concentric left ventricular hypertrophy (LVH), which in most cases is symmetric. Mild thickening of the left-sided valves is seen in as many as a quarter of patients. Severe aortic stenosis is an extremely rare disorder in FD. In this report, we describe the case of a 57-year-old male, who was diagnosed with a cardiac variant of FD 10 years ago. Since the patient had severe LVH, he was started on enzyme replacement therapy when he was 47 years old with an intravenous infusion of 0.2 mg/kg of agalsidase alpha every 14 days. The patient remained stable and asymptomatic for 9 years, until he presented with dyspnoea in New York Heart Association functional class II–III and severe aortic stenosis (aortic valve area: 0.97 cm2) together with severe systolic dysfunction [ejection fraction (EF): 29%]. Because of the patient’s comorbidities and high surgical risk, he underwent successful transfemoral transcatheter aortic valve implantation (TAVI). At 2 months following TAVI, the patient was asymptomatic and, in spite of his Fabry cardiomyopathy, the EF had increased to 45%. To our knowledge, this is the first case in the literature to demonstrate a rapid progression of aortic stenosis with severe impairment of left ventricular function and worsening in functional class in a patient with FD, who following TAVI improved his EF, with disappearance of symptoms and ventricular arrhythmias.

1 January 2021 in Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
OPOmar Prieto
Omar Prieto
TCTomás Francisco Cianciulli
Tomás Francisco Cianciulli
ASAlejandro Stewart-Harris
Alejandro Stewart-Harris
ARAndrea Rodriguez
Andrea Rodriguez
MSMaría Cristina Saccheri
María Cristina Saccheri
JGJuan Alberto Gagliardi
Juan Alberto Gagliardi
Prieto O, et al. J Cardiovasc Imaging. 2020 Oct;29:e31. https://doi.org/10.4250/jcvi.2020.0192